Dr. Reddy's completes acquisition of U.S. penicillin facility, products from GSK
HYDERABAD, India — Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.
The generic drug maker said it completed the acquisition of the facility and related product portfolio, including Augmentin and Amoxil brands. GSK will retain the existing rights for the aforementioned brands outside the United States.
Further financial terms and conditions of the transaction are not being disclosed.